Journal
CELL REPORTS
Volume 27, Issue 1, Pages 172-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2019.03.020
Keywords
-
Categories
Funding
- UK Medical Research Council [MC_PC_15002]
- Wellcome Trust [204826/Z/16/Z]
- Townsend-Jeantet Prize Charitable Trust [1011770]
- RDM Prize Studentship
- Clarendon Fund
- Keble College de Breyne scholarship
- MRC [MC_PC_15002] Funding Source: UKRI
Ask authors/readers for more resources
We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted with modified vaccinia virus Ankara. Among 82 antibodies isolated from peripheral blood B cells, almost half neutralized GP pseudotyped influenza virus. The antibody response was diverse in gene usage and epitope recognition. Although close to germline in sequence, neutralizing antibodies with binding affinities in the nano-to pico-molar range, similar to affinity matured antibodies from convalescent donors, were found. They recognized the mucin-like domain, glycan cap, receptor binding region, and the base of the glycoprotein. A cross-reactive cocktail of four antibodies, targeting the latter three non-overlapping epitopes, given on day 3 of EBOV infection, completely protected guinea pigs. This study highlights the value of experimental vaccine trials as a rich source of therapeutic human monoclonal antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available